Transcripta Bio Overview
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$24M
- Investors
-
6
Transcripta Bio General Information
Description
Developer of an artificial intelligence-driven drug discovery platform designed for accelerating therapeutic development. The company's platform integrates experimentation and computation to generate high-resolution transcriptomic data, utilizes proprietary gene expression analytics, and synthesizes molecules for validation, enabling pharmaceutical researchers and clinicians to identify therapeutic opportunities across a wide range of human diseases and predict biological responses, thereby improving the efficiency and precision of drug discovery.
Contact Information
Website
www.transcriptabio.comCorporate Office
- 1804 Embarcadero Road
- Suite 201
- Palo Alto, CA 94303
- United States
Corporate Office
- 1804 Embarcadero Road
- Suite 201
- Palo Alto, CA 94303
- United States
Transcripta Bio Timeline
Transcripta Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 22-Jul-2026 | $24M | Completed | Clinical Trials - General | ||
| 3. Early Stage VC (Series A1) | 13-Aug-2024 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 05-Nov-2021 | $20M | $22.6M | Completed | Clinical Trials - General | |
| 1. Seed Round | 12-Oct-2020 | $2.56M | $2.56M | Completed | Clinical Trials - General |
Transcripta Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Transcripta Bio Comparisons
Industry
Financing
Details
Transcripta Bio Competitors (6)
One of Transcripta Bio’s 6 competitors is Genesis Molecular AI, a Venture Capital-Backed company based in San Mateo, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genesis Molecular AI | Venture Capital-Backed | San Mateo, CA | ||||
| Terray Therapeutics | Venture Capital-Backed | Monrovia, CA | ||||
| insitro | Venture Capital-Backed | South San Francisco, CA | ||||
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA |
Transcripta Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Transcripta Bio Patents
Transcripta Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026206865-A1 | Methods and compositions for modulating adipor2 expression | Pending | 24-Mar-2025 | ||
| WO-2026193281-A1 | Methods and compositions for modulating expression of rbm39 and/or msh3 | Pending | 13-Mar-2025 | ||
| WO-2026178410-A1 | Methods and compositions for treating 19q12 autism spectrum disorder | Pending | 21-Feb-2025 | ||
| WO-2026142892-A1 | Methods and compositions for treating or reducing pmp22 genetic expression in pmp22-related neuropathy | Pending | 23-Dec-2024 | ||
| EP-4753694-A1 | Omaveloxolone for treating or preventing mitochondrial dysfunction caused by surf1 leigh syndrome | Pending | 04-Aug-2023 | A61K31/277 |
Transcripta Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Transcripta Bio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mayo Clinic | Corporation | Minority | ||
| Omnimed Capital | PE/Buyout | Minority | ||
| Gaingels | Venture Capital | Minority | ||
| BlueYard Capital | Venture Capital | Minority | ||
| JAZZ Venture Partners | Venture Capital | Minority |
Transcripta Bio FAQs
-
Where is Transcripta Bio headquartered?
Transcripta Bio is headquartered in Palo Alto, CA.
-
What is the size of Transcripta Bio?
Transcripta Bio has 20 total employees.
-
What industry is Transcripta Bio in?
Transcripta Bio’s primary industry is Drug Discovery.
-
Is Transcripta Bio a private or public company?
Transcripta Bio is a Private company.
-
What is Transcripta Bio’s current revenue?
The current revenue for Transcripta Bio is .
-
How much funding has Transcripta Bio raised over time?
Transcripta Bio has raised $56.6M.
-
Who are Transcripta Bio’s investors?
Mayo Clinic, Omnimed Capital, Gaingels, BlueYard Capital, and JAZZ Venture Partners are 5 of 6 investors who have invested in Transcripta Bio.
-
Who are Transcripta Bio’s competitors?
Genesis Molecular AI, Terray Therapeutics, insitro, Exscientia, and Numerion Labs are some of the 6 competitors of Transcripta Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
